For further information, please refer to the Current Report on Form 8-K to be filed by MiMedx Group, Inc. with the SEC as soon as practicable and the Proxy Statement on Schedule14A filed by Alynx, Co. with the SEC on March 10, 2008, accessible at: http://www.sec.gov/edgar/searchedgar/companysearch.html . You may also contact Matthew J. Miller, Executive Vice President of MiMedx Group, at 813-866-0000, for additional information.
This press release contains certain statements that may be considered
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended. Such statements may be identified by
their use of terms or phrases such as "expects," "estimates," "projects,"
"believes," "anticipates," "plans," "intends," and similar terms and
phrases. Forward-looking statements are based upon the current beliefs and
expectations of our management and are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified, which could
cause future events and actual results to differ materially from those set
forth in, contemplated by, or underlying the forward-looking statements.
For example, MiMedx and SpineMedica may be unable to continue their efforts
on particular products due to future laboratory results. We disclaim any
obligation to update or revise any forward-
|SOURCE MiMedx Group, Inc.|
Copyright©2008 PR Newswire.
All rights reserved